Pancreatic endocrine tumors are rare tumors classified into "functioning" and "nonfunctioning" tumors. A 68-year-old man was admitted to our hospital with the chief compliant of abdominal pain. Various imaging studies demonstrated a mass in the head of the pancreas with intraductal growth into the main pancreatic duct and an intraportal mass. The patient underwent a curative surgical operation. Histopathological examination revealed that it was nonfunctioning endocrine carcinoma of the pancreas. This is the first reported case of a pancreatic endocrine tumor with intraductal growth into the main pancreatic duct and tumor thrombus within the portal vein.
Introduction
Pancreatic endocrine tumors are rare, an estimated frequency being less than 1/100,000 of the population (1) . Generally they are classified into "functioning" and "non-functioning" tumors. The functioning tumors generally manifest symptoms earlier and are small compared with nonfunctioning tumors, and they present a mass effect, local invasion or metastases (2). Nonfunctioning endocrine tumors are clinically important because they have a high frequency of malignancy, ranging from 60% to 92% (3, 4). Since endocrine tumors present an expansive growth, oppression and deviation of the main pancreatic duct or portal venous system are commonly seen. Intraductal growth into the main pancreatic duct and simultaneous tumor thrombus in the portal vein, as in the present case, are rare features for a nonfunctioning endocrine tumor. Here, we present a case of nonfunctioning endocrine tumor of the pancreas.
Case report
A 68-year-old Japanese man was hospitalized because of upper abdominal pain in August 2005. He had diabetes mellitus since 1982, but had no personal or family history of pancreatic disease. The abdomen was soft; no mass was palpable. Results of laboratory tests were as follows: serum amylase, 216 IU/L (normal range: 43-131 IU/L); lipase, 122 U/mL (13-49 IU/L); trypsin, 1430 ng/mL (101-480 ng/mL); elastase-I, 571 ng/dL (<400 ng/dL); and white blood cell count, 5900/μ L (3500-9300/μ L). The fasting blood glucose level was 119 mg/dL (<110 mg/dL), and hemoglobin A 1C was 7.4% (<5.8%). Tumor marker values were as follows: carcinoembryonic antigen, 3.6 ng/mL (1.0-6.5 ng/mL); carbohydrate-associated anigen 19-9, 53.4 U/mL (<37 U/mL); and DUPAN-2, 75 U/mL (<150 U/mL). Pancreatic hormone was as follows: insulin, 5.4 μ U/mL (<9.9μ U/mL); glucagon, 112 pg/mL (<180 pg/mL); gastrin, 178.23 pg/mL (<200 pg/mL). confirming that the mass was a viable vascularized tumor rather than thrombus within the vein. Gross appearance of the resected specimen was a white nodular mass with cystic change, measuring 29×26 mm. The nodular mass in the pancreas had spread into the main pancreatic duct and protruded into the portal vein ( Fig. 2) . Microscopically, the tumor consisted of a large amount of fibrovascular stroma, and small, relatively uniform cuboidal cells with centrally located hyperchromatic nuclei, elevating mitotic index (>10 per 10 high-power fields), and eosinophillic cytoplasm ( Fig. 3 ).
Immunohistochemical staining with chromogranin-A and neuron-specific enolase was strongly positive in the tumor mass. However, the tumor was negative for anti-insulin, gastrin, glucagon, somatostatin, and pancreatic peptide antibody. According to the World Health Organization classification, a definitive diagnosis of pooly-differentiated endocrine carcinoma of the pancreas was made. As diabetes mellitus worsened postoperatively, insulin treatment was administered. Pancreatic hormone was as follows: insulin, 3.3μ U/mL (<9.9μ U/mL); glucagon, 118 pg/mL (<180 pg/mL); gastrin, 131.6 pg/mL (<200 pg/mL); the values were not significantly different from preoperative values. Since then the postoperative course was uneventful. However, at postoperative 7 months, tumor recurrence of multiple liver metastasis occurred. We performed systemic chemotherapy with streptozotocin and others, which was unsuccessful. At postoperative 11 months, the patient died from liver failure.
Discussion
We herein described a case of a nonfunctioning endocrine tumor with intraductal growth into the main pancreatic duct and tumor thrombus in the portal vein. Endocrine Pancreatic endorcine tumor with intraductal growth is thought to be very rare. There have been only 6 cases of nonfunctioning endocrine tumors that extended into the lumen of the main pancreatic duct (8-12), and 5 of them were diagnosed as malignant tumors (Table 1) . Thus, intraductal growth of nonfunctioning endocrine tumors into the main pancreatic duct is thought to indicate malignant behavior of the tumor. In particular, the present case presented a unique pattern in terms of extension of the tumor into the main pancreatic duct and intraductal growth, giving rise to increased levels of serum pancreatic enzymes. Extrinsic venous involvement is a common feature of pancreatic ductal adenocarcinioma. However, it is a rare feature for nonfunctioning endocrine tumors; few cases with venous occlusion, venous encasement, or intraportal growth have been reported (13) . There is no report of intraductal growth and tumor thrombus simultaneously caused by endocrine tumors as in the present case as far as we know based on a MEDLINE search for the period from 1983 to September 2006 of the following key words: endocrine tumor, intraductal growth, portal vein thrombus and intraportal growth.
The origin of the tumor remains controversial, and several hypotheses for this unique growth may be proposed. However, it is strongly speculated that such tumor arises from islets or ducts adjacent to the main pancreatic duct (14, 15) . It should be noted that the tumor in the present case expanded into the lumen of the main pancreatic duct without invading the pancreatic epithelium, unlike ductal adenocaricinoma. For such a case where intraportal growth is observed, close follow-up is needed even after radical treatment because circular recurrence can occur (particularly liver metastasis) at high frequency.
In summary, we reported a rare case of a nonfunctioning endocrine tumor of the pancreas that uniquely grew within the lumen of the main pancreatic duct with development of venous thrombus. EUS was very helpful to delineate the intraportal growth of the tumor, and ERP to delineate the intraductal growth of the tumor. These are very unusual characteristics for an endocrine tumor. Please note that there is a spelling change necessary in Table 1 
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